FDA approves Duchenne muscular dystrophy drug

September 27, 2016

The FDA has approved of an innovative new treatment for Duchenne muscular dystrophy. The drug was developed by researchers from Murdoch University.

Video above: Murdoch University researchers Steve Wilton and Sue Fletcher discuss their new drug for Duchenne muscular dystrophy.

The powerful US Food and Drug Administration (FDA) has given the green light to a drug developed by Western Australia researchers Sue Fletcher and Steve Wilton for treating Duchenne muscular dystrophy.

The Murdoch University scientists developed an innovative treatment to help sufferers of Duchenne muscular dystrophy, a crippling muscle-wasting disease that affects about one in 3500 boys worldwide.

The FDA decision is a huge win for the global pharma company Sarepta Therapeutics, which has developed the drug under the name Eteplirsen.

In their breakthrough research, Fletcher and Wilton had devised a way to bypass the faulty gene responsible for the disease, using a technique called exon skipping.

The FDA’s approval follows an emotional campaign by sufferers, their families, and supporters of Eteplirsen.

Earlier this year, some 40 sufferers in wheelchairs and their families flew to Washington from around the US, and from as far as the UK, to show their faith in the treatment after authorities questioned aspects of the drug’s clinical trial.

Fletcher’s and Wilton’s innovative discovery had already won the 2012 WA Innovator of the Year Award.

In 2013, the researchers, then with UWA, signed a multi-million dollar deal with Sarepta to develop Eteplirsen.

Under the deal, they would get up to US$7.1 million in upfront and milestone payments, as well as royalties on the net sales of all medicines developed and approved.

– Tony Malkovic 

This article was first published by Science Network Western Australia on 21 September 2016. Read the original article here. 

Read next: CtX forges $730 m deal for new cancer drug. A promising new cancer drug, developed in Australia by the Cancer Therapeutics CRC (CTx), has been licensed to US pharmaceutical company Merck in a deal worth $730 million.

Related stories

Leave a Reply

Your email address will not be published. Required fields are marked *